Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opportunities to Optimize Cancer Policies Panel Discussion

Aug

Today In Oncology

Opening Session Panel Discussion

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opportunities to Optimize Cancer Policies Panel Discussion

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL

FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer

ACS Study Quantifies Financial Burden of Cancer in Older Patients